Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models by Di Niro, Roberto et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
Construction of miniantibodies for the in vivo study of human 
autoimmune diseases in animal models
Roberto Di Niro†1, Federica Ziller†1, Fiorella Florian1, Sergio Crovella2, 
Marco Stebel3, Marco Bestagno4, Oscar Burrone4, Andrew RM Bradbury5, 
Paola Secco6, Roberto Marzari1 and Daniele Sblattero*6
Address: 1Department of Biology, University of Trieste, 34127 Trieste, Italy, 2Department of Reproductive and Development Science, University 
of Trieste, 34127 Trieste, Italy, 3CSPA, University of Trieste, 34127 Trieste, Italy, 4International Centre for Genetic Engineering and Biotechnology, 
34012 Trieste, Italy, 5Bioscience Division, Los Alamos National Laboratory, 87545 Los Alamos, NM, USA and 6Department of Medical Sciences, 
IRCAD, University of Eastern Piedmont, 28100 Novara, Italy
Email: Roberto Di Niro - rdiniro@units.it; Federica Ziller - federicaler@virgilio.it; Fiorella Florian - florian@units.it; 
Sergio Crovella - crovella@burlo.trieste.it; Marco Stebel - stebel@units.it; Marco Bestagno - bestagno@icgeb.org; 
Oscar Burrone - burrone@icgeb.org; Andrew RM Bradbury - amb@lanl.gov; Paola Secco - psecco@med.unipmn.it; 
Roberto Marzari - marzari@units.it; Daniele Sblattero* - daniele.sblattero@med.unipmn.it
* Corresponding author    †Equal contributors
Abstract
Background: Phage display antibody libraries have been made from the lymphocytes of patients
suffering from autoimmune diseases in which the antibodies are known to play a role in the
pathogenesis or are important for the diagnosis of the disease. In the case of Celiac Disease, the
immune response is directed against the autoantigen tissue transglutaminase. However, despite
numerous studies, the role of these antibodies in the pathogenesis of this disease has not been
elucidated.
Results: We were able to engineer specific anti-transglutaminase antibody fragments in the form
called "miniantibody". These are produced by genetic fusion of anti-tTG scFv to Human, Mouse or
Rat Fc domains, making them suitable for in vivo expression. The results obtained here indicate
that the miniantibody molecule is efficiently secreted, and that the reactivity to the antigen is
retained even after fusion to heterologous Fc domains. Further analysis demonstrate that the
molecule is secreted as homodimeric, mimicking original antibody structure. Finally, the in vivo
expression in mice leads to detectable serum levels with no apparent gross immune response by
the host.
Conclusion: In this work we demonstrated the usefulness of a method for the in vivo expression
of miniantibodies specific to transglutaminase, corresponding to the autoimmune specificity of
Celiac Disease. This can be proposed as a general method to study the pathogenic role of
autoimmune antibodies in autoimmune diseases.
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Background
Autoimmunity is an important cause of disease in
humans, it is estimated to affect at least 3% to 5% of the
human population and depends on a failure of the mech-
anisms normally responsible for maintaining self-toler-
ance (for a review see [1]). Although many factors causing
these diseases, including the genes that may predispose to
autoimmunity, have been identified, the aetiology of
most autoimmune diseases remains obscure. Much inter-
est has focused on the analysis of the immune factors
leading to the tissue lesions. In some cases the cellular
immune response stimulated by lymphokines seems to
play a major role, whereas in others the humoral antibody
response is deemed prevalent. Functional genomics may
offer a solution to these problems by using biological sys-
tems which allow the massive interaction between an
autoimmune patient's cloned antibody repertoire and
individual antigens. One of these systems is phage dis-
play, a technique which involves the coupling of pheno-
type to genotype in a selectable format. It has been
extensively used in molecular biology to study protein-
protein interactions and one of the most successful appli-
cations of phage display has been the isolation of mono-
clonal antibodies to purified antigens [2-5]. In addition to
libraries from naive or immunized sources, phage anti-
body libraries have also been made from patients suffer-
ing from autoimmune diseases. This work has been most
extensively carried out with thyroid disease [6], systemic
lupus erythematosus [7], paraneoplastic encephalomyeli-
tis [8], myasthenia gravis [9] and type 1 diabetes mellitus
[10]. In a recent work we described the antibody response
in Celiac Disease (CD) [11]. This is a genetic illness
strongly linked to HLA DQ2, characterized by flattening
of the intestinal mucosa and malabsorption. The patho-
genesis is precipitated by dietary exposure to wheat gluten
and similar proteins in rye, barley and possibly oats [12].
The disease is characterized by the presence of specific
antibodies recognizing gliadins, food proteins and an
endomysial autoantigen, identified as tissue transglutam-
inase (tTG) [13]. We recently made and selected phage
antibody libraries from the DNA isolated from CD patient
lymphocytes and were able to isolate single-chain anti-
body fragments (scFv) to tTG showing their specific pro-
duction by intestinal lymphocytes, indicating that the site
of synthesis of these antibodies is the intestinal mucosa
[11]. ScFvs isolated from different patients recognized the
same tTG epitopes and by ELISA competition experiments
we demonstrated that the number of epitopes recognized
was restricted to two, distinguished by the ability of the
antibodies to recognize mouse tTG [14]. The activities of
these in vitro selected antibodies mimics those found in
the serum of CD patients, and preliminary work suggests
similar biological activity indicating that in vivo studies of
these antibodies may provide useful information on the
pathogenic roles of these antibodies in CD.
The isolation of disease-specific antibodies, as well as the
related gene, is the first step in the generation of animal
models through in vivo antibody gene expression. In vivo
gene expression has been implemented using a number of
different techniques, including injection of naked DNA
into the muscle, with or without electroporation [15],
coating gold particles with DNA and injecting them with
a gene gun [16]. However, expression of recombinant pro-
tein is usually transient and only low levels are reached,
using these methods. Recently gene transfer systems medi-
ated by vectors based on the adeno-associated virus, have
been shown to mediate sustained and prolonged titres of
engineered antibody [17-19].
In the present work we describe the production of a series
of miniantibody constructs composed of a human
autoimmune anti-tTG scFv combined with antibody con-
stant Fc regions from human, rat and mouse. This was
sought as a simple approach to rapidly obtain sustained in
vivo production of antibodies with specific specificities. In
addition to providing appropriate effectors domains,
fusion to constant regions also prolongs half life. This rep-
resents an innovative tool for the in vivo studies of the
pathogenic properties of cloned autoimmune antibody
fragments.
Results
In a previous paper [11] we described the isolation of
human IgA scFvs to tTG from phage antibody libraries
obtained from the intestinal lymphocytes of CD patients.
Two of these scFvs, indicated as 2.8 tTG, cross-reactive to
rodent tTG, and 3.7 tTG, specific for human enzyme, were
the reference antibody fragments used to make the series
of constructs reported in Fig. 1. The construction of the
series pMB-SV5 is reported in Materials and Methods sec-
tion. It is characterized by a BssHII-NheI cassette for the
subcloning of scFvs from the pDAN5 phagemid vector, a
NheI-SpeI cassette for the cloning of CH2 and CH3
domains of Fc from different species, and an SV5 tag at the
3' end for uniform detection. Expression of the minianti-
bodies was driven by a CMV promoter and a leader
sequence at the N-terminus was included to allow mam-
malian secretion. The two selected scFvs (2.8 tTG and 3.7
tTG) were cloned into the 4 different vectors, generating a
total of 8 different constructs. All vectors were checked by
DNA sequencing and the purified plasmidic DNAs were
transfected into HEK 293T cells. The secretion of the min-
iantibodies in the culture medium was analyzed after 72
h by ELISA on plates coated with either human or mouse
tTG. The results, determined by recognition of the SV5 tag
at the C-terminus of the constructs (Fig. 2A), or with spe-
cies specific antibodies (Fig. 2B), for the 2.8 miniantibod-
ies show that they were all able to recognize both antigens
with O.D. values ranging from 0.5 (MB-HuA-2.8) to 1.6
(MB-MoG-2.8). Similar results were obtained with the 3.7BMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
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miniantibodies, except that recognition was specific for
the human enzyme, with no binding to mouse tTG (Fig.
2C and 2D).
Stable cell lines for all the constructs were established by
growing transfected cells in the selective agent for hygro-
micin resistance. Supernatant from individual clones were
screened for the best ELISA reactivity and then expanded
for further experiments. The average yield of minianti-
body production was in the 5–10 mg/liter range using
standard culture flask.
The miniantibodies were analyzed by Western blotting
under reducing and non reducing conditions and after
treatment of the purified miniantibodies with glycosidase
PNGaseF to assay the level of glycosylation. The results for
the miniantibody MB-MoG-2.8 are reported, as an exam-
ple, in Fig. 3A. The predicted molecular weight of the min-
iantibodies, result of the fusion of the scFv with constant
domains and SV5 tag, is about 55 kDa.
We found bands of the predicted molecular weight in the
samples treated with reducing agent and a slight increase
in the electrophoretic mobility in the deglycosylated sam-
ples, indicating that the miniantibodies are glycosylated
in HEK 239T cells. Under non reducing, non denaturing
conditions, a high molecular weight band, explained by
the interchain disulfide bond in the Hinge region, was
obtained.
The ability of the miniantibodies to activate the classic
complement pathway was tested with an in vitro assay, as
reported in Fig. 4, in which C1q deposition was measured
using an ELISA assay. The results showed that human and
rat miniantibodies, of IgG1 and IgG2b origin respectively,
were able to bind C1q, the first component of the classic
complement cascade, as described in the literature
[20,21], whereas the mouse miniantibody of IgG1 origin
could not bind C1q [22].
The miniantibodies were analyzed for their ability to rec-
ognize tTG on histological sections. These experiments
were undertaken in view of the possible use of these min-
iantibodies in in vivo studies. The immunolabeling of his-
tological sections of mouse muscle is shown in Fig. 3B,
using purified MB-MoG-2.8 and 3.7. Staining was only
detected for MB-MoG-2.8 with specific recognition of the
extracellular tTG present at the muscular endomysium
and perimysium. The same pattern was found when min-
iantibodies with the human or rat Fc were used (not
shown). For the same reasons, an assay on the inhibition
of tTG activity by miniantibodies was tested. We have
already shown that scFvs to tTG isolated from the intesti-
nal lymphocytes of CD patients inhibit the in vitro
transamidation activity of tTG [23]. Fig. 5 shows that the
coupling of 5-(biotinamido)pentylamine to gliadin (a
tTG substrate) is catalyzed by mouse purified recom-
binant tTG, which is inhibited by miniantibody MB-MoG-
2.8, but not miniantibody MB-MoG-3.7, confirming the
specificity observed by ELISA. The inhibition closely mir-
rors the values previously described for the scFv [23] in a
similar assay. In comparing the two miniantibodies with
the commercial tTG-specific monoclonal antibody
ELISA of supernatants of cultured HEK 293T cells trans- fected with the series of plasmids pMB-SV5 carrying 2.8 scFv  gene (A and B) and 3.7 scFv gene (C and D) fused to CH2- CH3 domains genes from human, mouse and rat Figure 2
ELISA of supernatants of cultured HEK 293T cells trans-
fected with the series of plasmids pMB-SV5 carrying 2.8 scFv 
gene (A and B) and 3.7 scFv gene (C and D) fused to CH2-
CH3 domains genes from human, mouse and rat. Antigens: 
human tTG, mouse tTG and BSA. Secondary antibodies: A) 
and C) biotinylated mAb SV5 and streptavidin conjugated 
with peroxidase; B) and D) goat anti human, mouse and rat 
IgG or IgA conjugated with peroxidase.
Schematic representation of the cloning vector Figure 1
Schematic representation of the cloning vector. The Human 
IgG1 CH2-CH3 domains gene in the vector pMB-SV5 could 
be substituted by Human IgA, Mouse and Rat Fc domain 
genes using restriction sites NheI and SpeI. Different scFvs 
can be exchanged by using restriction sites BssHII and NheI.BMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
Page 4 of 10
(page number not for citation purposes)
CUB7402, the results show that the percentage of enzyme
activity inhibition is higher with the miniantibodies com-
pared to CUB7402, using the same enzyme to antibody
ratio. We believe that this is due to both a difference in
affinity and the different epitope recognized by the CD
derived antibodies.
The in vivo expression of selected miniantibodies was
studied by using DNA vaccination protocols. According to
this method of gene transfer, DNA is delivered directly to
the muscle of the animal where it is internalized by the
muscular fibers and expressed if an appropriate eukaryotic
promoter is present. In our case, in order to evaluate the
possibility of using miniantibodies for in vivo studies of
the biological activities of autoimmune antibodies, we
used an anti-tTG scFv that recognizes mouse tTG, and a
second construct which did not cross-react with rodent
tTG. In the latter case, the purpose was to monitor the
serum level of an antibody not sequestered by tTG at the
tissue level, which may occur, if an antibody recognizing
mouse tTG is used. 50 μg of purified pMB-MoG-2.8 and
pMB-MoG-3.7 DNA were injected twice into the quadri-
ceps of eight BALB/c mice at an interval of 14 days. The
mice were periodically examined for the presence of reac-
tive miniantibodies to tTG at serum levels by ELISA. As
outlined in Fig. 6, for both constructs low but detectable
levels of miniantibodies to tTG were measured in the
blood samples taken up to 40 days after the injection.
Mouse sera were also investigated for the possible pres-
ence of antibodies raised against the miniantibody mole-
cule. This was done by ELISA, adsorbing purified MB-
MoG-2.8 and MB-MoG-3.7 on plastic wells. No evidence
of an induced immune response was found, with sera
from the 2.8 or 3.7 treated mice all negative at 40 days
(data not shown). At the end of the experiments the mice
were sacrificed and the hindquarter muscle examined by
in situ PCR for the presence of miniantibodies DNA. The
result, depicted in Fig. 7, showed a positive labeling for
scattered muscular fibers, indicating the continued pres-
ence of the plasmid DNA.
Discussion
Engineered antibodies are increasingly being used as ther-
apeutic agents in numerous cases including oncology,
autoimmunity, inflammation and infectious diseases
[24]. Combinatorial approaches have been applied to
scFvs isolated from phage display libraries, modifying the
reactive V regions by fusion with a range of molecules to
improve the antibody stability and avidity [25,26], to alter
the effector functions [27,28], to balance the pharmacok-
inetics [29], to facilitate the purification [30], or to com-
bine different antibodies giving rise to bifunctional
antibodies [31-33]. In the case of the present work, the
fusion of human autoimmune scFvs to the Fc domains of
different species had the goal of using such constructs for
expression in vivo and possibly generate an autoimmune
animal model. Such direct scFv-Fc fusions have been
widely used and expressed in yeast [34,35] and mamma-
lian cells [36,37], with activity similar to full length IgGs
in most assays, with the advantages of dimerization and
effector functions, provided by the fused Fc domain. The
most critical passage of this approach was the preservation
of the antibody reactivity after fusion with Fc domains
from other species. This was implemented by the creation
Complement fixation assay with the miniantibodies con- structs MB-HuG-2.8 and 3.7, MB-MoG-2.8 and 3.7, MB-RaG- 2.8 and 3.7 Figure 4
Complement fixation assay with the miniantibodies con-
structs MB-HuG-2.8 and 3.7, MB-MoG-2.8 and 3.7, MB-RaG-
2.8 and 3.7. The binding of C1q to the miniantibodies is 
revealed with biotinylated anti-C1q and streptavidin conju-
gated with alkaline phosphatase. Positive and negative control 
are represented by the murine anti-His D8 (IgG2a) and 
CUB7402 (IgG1) mAb, both recognizing the coated tTG.
A, Western blotting of the miniantibody MB-MoG-2.8 with  reducing agents (lane 2), treated with glycosidase PNGase F  (lane 1), and in not reducing not denaturing conditions (lane  3) Figure 3
A, Western blotting of the miniantibody MB-MoG-2.8 with 
reducing agents (lane 2), treated with glycosidase PNGase F 
(lane 1), and in not reducing not denaturing conditions (lane 
3). B, Immunohistochemistry performed on histological sec-
tion of mouse muscle tissue with the miniantibodies con-
structs MB-MoG-2.8 and 3.7. Secondary antibodies: 
biotinylated mAb SV5 followed by streptavidin conjugated 
with alkaline phosphatase (western blotting) or horseradish 
peroxidase (immunohistochemistry).BMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
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of a novel mammalian expression vector in which either
scFv or Fc domain could be easily switched using compat-
ible restriction sites. As demonstrated by ELISA, all the
chimeric constructs recognized the tTG antigen, and west-
ern blotting showed the expected higher molecular weight
bands corresponding to the dimeric form. The binding
activity of the constructs with the scFv 2.8, crossreactive to
rodent tTG, was also preserved to mouse tTG tested in
ELISA as well as in an immunochemical assay on histolog-
ical section of mouse muscle, as was the ability to inhibit
the crosslinking activity of tTG. Complement activation
measured by C1q deposition was confirmed for the
human and rat miniantibody constructs reflecting the
presence of the CH2 domain and correct glycosylation
produced by the transfected 293T cell.
Injection of plasmid DNA was used to induce in vivo
expression of miniantibodies. This approach derives from
extensive studies on DNA vaccination in which naked
plasmid DNA, coding for an antigenic protein, is trans-
fected into muscle cells in vivo either by injection [38,39]
or using a "gene gun" [40]. This results in expression of
the vector-encoded antigen, which induces cellular and
humoral responses [41]. In a similar vein, injection of
DNA coding for an anti-tumoral scFv has also been carried
out [42]. Although other studies have demonstrated both
cellular and humoral responses against human scFvs in
mice [43] with a reduction of the therapeutic potential,
this feature can also be exploited to generate anti-idiotypic
responses against scFvs derived from mouse lymphomas
[44,45].
Inhibitory effect of purified MB-MoG-3.7 (grey bars), MB- MoG-2.8 (black bars) and mAb CUB7402 (hatched bars) on  mouse tTG activity Figure 5
Inhibitory effect of purified MB-MoG-3.7 (grey bars), MB-
MoG-2.8 (black bars) and mAb CUB7402 (hatched bars) on 
mouse tTG activity. Elisa plates coated with gliadin, a tTG 
substrate, are incubated with 0.2 mM 5-(biotina-
mido)pentylamine and 0.25 μg of mouse tTG, with increasing 
amounts of purified miniantibody or mAb. The incorporation 
of 5-(biotinamido)pentylamine is revealed by streptavidin 
conjugated with peroxidase.
ELISA time course of the serum anti-tTG miniantibody aver- age titer in 8 BALB/c mice injected at 0 and 14 days with  pMB-MoG-3.7 (panel A) and 2.8 (panel B) DNA Figure 6
ELISA time course of the serum anti-tTG miniantibody aver-
age titer in 8 BALB/c mice injected at 0 and 14 days with 
pMB-MoG-3.7 (panel A) and 2.8 (panel B) DNA. Serum dilu-
tion 1:50. Secondary antibodies: biotinylated mAb SV5 and 
streptavidin conjugated with peroxidase.
In situ PCR on histological section of quadriceps muscle of a  mouse injected with pMB-MoG-3.7 construct Figure 7
In situ PCR on histological section of quadriceps muscle of a 
mouse injected with pMB-MoG-3.7 construct. PCR was per-
formed after 40 days since injection. The arrows point at 
cells with positive reaction.BMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
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In these experiments, the effectiveness of the anti-idio-
typic response was enhanced by fusing the cloned anti-
body expressed by the tumoral cells to an additional CH3
antigenic region, as originally suggested by Syrengelas et
al. [46]. In the present study, since a human scFv xeno-
genic for mice was used, we sought to minimize the host
immune response by using the scFv fused to a CH2-CH3
syngenic mouse Fc region. The outcomes of the experi-
ments have confirmed the validity of this approach, with
a detectable production of miniantibodies in the serum
for at least 40 days and a peak of production after 20 days.
Conclusion
The reactivity of the serum miniantibodies in ELISA
together with the apparent lack of humoral response
against the miniantibody molecule, led us to conclude
that the human scFv-mouse Fc fusion miniantibodies are
poorly immunogenic in the mouse under the experimen-
tal conditions used here. In conclusion, our results indi-
cate that chimeric proteins generated by fusion of human
scFvs to human, murine and rat Fc regions are effectively
produced and secreted by cultured cells; the polypeptides
dimerize, forming disulfide bridges, so increasing the
valency of the miniantibody; the miniantibodies retain
the antigen recognition both in ELISA and immunohistol-
ogy and the ability to activate complement. The inhibitory
properties of the scFv are preserved and, upon intramus-
cular injection of the plasmid, the ELISA antibody titre is
still detectable after 40 days, suggesting the absence of an
immune response by the host when a syngenic Fc frag-
ment is present in the construct. While this indicates that
the approach is functional and will be useful in the in vivo
study of the role of autoimmune antibodies, in the
absence of complicating immunological factors, the
period of expression obtained here is relatively short
when compared to the long time scale involved in most
autoimmune diseases, which occurs over a period of
years. For this reason it may be appropriate to explore
alternative in vivo expression methods, such as adeno-
associated virus vector, which has been shown to induce
expression over a prolonged period.
Methods
Bacterial strains and enzymes
DH5aF' (F'/endA1 hsdR17 (rK- mK+) supE44 thi-1 recA1
gyrA (Nalr) relA1 D (lacZYA-argF)U169 deoR
(F80dlacD(lacZ)M15)) strain was used for the cloning of
pDAN5, pMB-SV5 and derivates, pCDNA3.1/Hygro(+)
and pTrcHisB. Molecular biology enzymes were pur-
chased from New England Biolabs, Promega or Life Tech-
nologies.
Antigens
Human tTG gene was cloned in pTrcHisB as described
[47]. Mouse tTG gene was cloned in pTrcHisB as described
[48]. Protein purification was performed as described in
[14].
RNA extraction and cDNA synthesis
Peripheral blood lymphocytes from a healthy donor and
spleen lymphocytes from mouse and rat were separated
by density gradient centrifugation on Ficoll Hypaque
(Pharmacia). Total RNA was then prepared as described
[49]. cDNA was prepared using SuperScript II Reverse
Transcriptase (Gibco BRL) with random hexamers.
pCDNA3.1/Hygro(+) modification
pCDNA3.1/Hygro(+) plasmid vector (Invitrogen) was
modified as follows: NheI restriction site was exchanged
with XbaI, PmeI site was exchanged with HindIII site by
inverse polymerase chain reaction (PCR) using the prim-
ers Hygro-XbaI-INV antisense and Hygro-HindIII-INV
sense; the primers are reported as A and B in Table 1. ScFv
2.8 [11] was PCR amplified from pDAN plasmid vector by
successive amplification with sense primers 1-XbaI-leader,
2-leader-intron and 3-BssHII-scFv (Table 1, primers 1, 2
and 3), which introduce the XbaI site, a secretion leader
and a mini-intron as described in [50] and the BssHII site
Table 1: Primers. List of oligonucleotides used for vector construction and Fc region cloning.
Number Name Orientation Sequence
A Hygro-XbaI-inv Antisense AGCTTCTAGACAGCTTGGGTCTCCCTATAG
B Hygro-HindIII-inv Sense AGCTAAGCTTAAACCCGCTGATCAGC
1 1-XbaI-leader Sense CAGGCGTCTAGATGCCACCATGGGCTGGAGCCTGATCCTCCTGTTCCTCGTCGCTGTGGCTACAGGTAAGGG
2 2-leader-intron Sense TGTGGCTACAGGTAAGGGGCTCACAGTAGCAGGCTTGAGGTCTGGACATATATATGGGTGACAATGACATCCAC
3 3-BssHII-scFv Sense GGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGGCGCGCATGCCGACATCCGGTTGACCCAG
4 scFv-NheI-HindIII Antisense CCGCTAAGCTTCGCCTGGCTAGCAAAAGCGTCCGTCGTATC
5 HuGCH2-s Sense AGGCGGCTAGCGACAAAACTCACACATGCCCACCGTGCCCA
6 HuGCH3-SV5-a Antisense CTGCTAAGCTTTTAAGTACTATCCAGGCCCAGCAGTGGGTTTGGGATTGGTTTGCCACTAGTTTTACCCGGGGAC
AGGGAGAG
7 HuACH2-s Sense CAGGCGGCT AGCGTTCCCTCAACTCCACCTACC
8 HuACH3-a Antisense CCGCTACTAGTTTTACCCGCCAAGCGGTCGAT
9 MoGCH3-a Antisense CCGCTACTAGTTTTACCAGGAGAGTGGGAGAG
10 MoGCH2-s Sense CAGGCG GCT AGC GGTTGTAAGCCTTGCATATGTACA
11 RaGCH3-a Antisense CCGCTACTAGTTTTACCCGGAGGCCGGGAGATG
12 RaGCH2-s Sense CAGGCG GCT AGC CACAAATGCCCTACATGCCCTBMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
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at the 5' end, and antisense primer scFv-NheI-HindIII
(Table 1, primer 4), which introduces the NheI and Hin-
dIII sites at the 3' end. PCR fragment was cloned as XbaI –
HindIII in the modified pCDNA3.1/Hygro(+) vector.
Cloning of Human Fc gene
The human IgG1 CH2 and CH3 domains gene was ampli-
fied from lymphocyte cDNA by using the primer sense
HuGCH2-s and antisense HuGCH3-SV5-a (Table 1, prim-
ers 5 and 6), which introduce SpeI site and the SV5 tag
sequence for mAb recognition [51] at the 3' end. PCR frag-
ment was cloned as NheI-HindIII into the pCDNA3.1/
Hygro(+) vector modified as described and carrying the
scFv 2.8; the resulting vector was named pMB-HuG-2.8.
The series of vector obtained by exchange of different scFv
and Fc was called pMB-SV5.
Exchange of constant domains and scFvs
The set of oligonucleotide primers for amplification of Fc
domain genes was designed to comprise the CH2-CH3
domains including the flexible hinge region. The CH2-
CH3 domain genes were PCR amplified by using the sense
primer HuACH2-s and antisense HuACH3-a for human
IgA, MoGCH2-s and MoGCH3-a for mouse IgG1,
RaGCH2-s and RaGCH3-a for rat IgG2b. All primers are
reported in Table 1. The PCR fragments were cloned in
pMB-HuG-2.8 vector replacing the resident Fc domain
gene by cutting with NheI and SpeI and ligation.
The cloning of 3.7 scFv gene was performed by extraction
of scFv gene from phagemid pDAN5 clone by cutting with
BssHII and NheI and direct cloning in the series of vectors
pMB-SV5 cut with the same enzymes.
HEK 293T transfection and selection
The human kidney derived HEK 293T cell line was cul-
tured in D-MEM medium (GIBCO) supplemented with
10% fetal calf serum (FCS). Cells were harvested by shak-
ing and plated in a 24 well microtiter plate (2 × 105 cells
per well). For transient transfection, after 24 h, 1 μg of
purified plasmid DNA resuspended in 50 μl of D-MEM
without FCS and 2 μl of Lipofectamine 2000 (Invitrogen)
in 50 μl of D-MEM were mixed, left at RT for 20 min and
added to each well of cultured cells. The cells were grown
for further 24/48 h and the supernatant inspected for min-
iantibody production. Stable cell clones secreting minian-
tibodies were obtained by treating the cells in the same
way as for the transient transfection, diluting the cells 1:10
with fresh medium after 24 h from transfection and add-
ing 400 μg/ml of antibiotic Hygromicin (Invitrogen) for
the selection of resistant cells. After 10 days of culture, the
Hygromicin concentration was reduced to 200 μg/ml.
ELISA
ELISA was performed by coating ELISA plates with puri-
fied human or mouse recombinant tTG at 10 μg/ml
diluted in phosphate-buffered saline (PBS) for 15 h at
4°C. Wells were blocked with 2% non-fat milk in PBS
(MPBS). The primary antibodies were the supernatants of
cultured HEK 293T cells diluted 1:5 with 2.5% MPBS or
sera of mice injected with plasmid DNA diluted 1:50 with
2% MPBS. Secondary antibodies used were biotinylated
mAb SV5 [51] recognizing the SV5 tag found at the mini-
antibody C-terminus and goat anti human, mouse and rat
IgG or IgA conjugated with peroxidase. The secondary
antibodies were used as following: a) biotinylated mAb
SV5 diluted 1:2000 with 2% MPBS, followed by streptavi-
dine conjugated with horseradish-peroxidase (HRP)
(Pierce) diluted 1:2000, b) goat anti human, mouse and
rat IgG or IgA conjugated with peroxidase (Dako) diluted
1:1000. Each step was followed by three washes with PBS
plus 0,1% Tween20 (PBST) and three washes with PBS.
All the immunocomplexes were revealed with tetrame-
thyl-benzidine (TMB) and read at O.D.450.
Serum-free cell cultures and Protein G purification
Serum-free supernatants for protein-G purification were
obtained as following: stable cell clones grown at conflu-
ence in 25 cm2 flasks were harvested, centrifuged at 1200
× g and resuspended in FCS-free D-MEM medium. Cells
were allowed to grow for further 48 h and the superna-
tants collected.
Miniantibodies produced in FCS-free cell culture superna-
tants were purified by using a HiTrap protein G column
(GE Healthcare) following standard procedures. Briefly,
50 ml of serum-free culture were passed through the pro-
tein G column; the column was washed with 20 ml of 100
mM Tris-HCl, pH 8.0, and 20 ml of 10 mM Tris-HCl, pH
8.0. Purified miniantibodies were eluted with 50 mM Gly-
cine, pH 3.0, and immediately buffered with Tris-HCl, pH
8.0.
tTG inhibition assay
ELISA plate wells were adsorbed with 20 μg/ml purified
gliadin for 2 h at 37°C and washed twice with PBS. To
each well 100 μl of a solution of 5-(biotina-
mido)pentylamine (Pierce) 0.2 mM, 0.25 μg of purified
mouse tTG in NaCl 150 mM, Tris 50 mM pH 7.5 with
increasing amount of either protein G purified minianti-
body or commercial tTG-specific monoclonal antibody
CUB7402 (Bio Optica, Milan), ranging from 0 to 0.5 μg
per microwell, were added. After 1 h incubation at 37°C,
the wells were washed three times with PBS plus 1%
Tween20 and three times with PBS. 100 μl of a solution of
streptavidin conjugated with alkaline phosphatase
(Pierce) 1:2000 in PBS 2% bovine serum albumin (BSA)
were added to each well and incubated for 1 h at RT. AfterBMC Biotechnology 2007, 7:46 http://www.biomedcentral.com/1472-6750/7/46
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extensive washing, the tTG activity, based on coupling of
5-(biotinamido)pentylamine to gliadin by tTG, was
revealed by adding 100 μl of 4-nitrophenyl phosphate
(pNPP) (Sigma) and read at O.D.405.
Complement fixation assay
The complement fixation assay was performed by coating
ELISA plates with recombinant human tTG at 100 μg/ml
for 15 h at 4°C. Wells were blocked with MPBS for 1 h and
then primary antibodies were incubated for 1 hr at RT.
Protein G purified miniantibodies were used as primary
antibodies, at a concentration of 0,5 μg per microwell in
2% MPBS. An anti-histidine tag murine monoclonal anti-
body of IgG2a isotype His-probe D8 (Santa Cruz) and a
commercial anti-tTG murine IgG1 CUB7402 (Neomar-
ker), both recognizing the coated tTG, were used diluted
1:500 in MPBS as a positive and negative control, respec-
tively. After three washes with PBST and three with PBS,
purified human complement component C1q (Quidel) 3
μg/ml in 0,1% MPBS with 0,05% Tween20 was incubated
for 1 hour. Following washes a biotin-labelled anti-C1q
antibody (Quidel) diluted 1:3000 in the same buffer of
C1q was incubated for 1 hour, followed by alkaline phos-
phatase (AP)-conjugated streptavidin (Pierce) 1:3000 in
PBS with BSA 2% for 45 minutes. Reaction was revealed
with 4-nitrophenyl phosphate (pNPP) (Sigma) and read
at O.D.405.
Western blotting
Sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS PAGE) under reducing conditions was per-
formed according to standard techniques. To perform SDS
PAGE under non-reducing conditions, proteins were
loaded in sample buffer without β-mercaptoethanol. To
assess glycosylation, samples were treated with or without
deglycosylase PNGaseF (New England Biolabs) according
to the manufacturer instructions. Cell culture superna-
tants containing miniantibody fractions were separated
by SDS PAGE and transferred onto nitrocellulose (Amer-
sham) by semi dry blotting using the Pharmacia Multi-
phor II. The membrane was blocked using 2% MPBS for 1
hour at room temperature. Biotinylated mAb SV5 was
used as primary antibody. After 2 h incubation at RT and
extensive washing with PBS plus 0.1% Tween20, the nitro-
cellulose was subsequently incubated with alkaline phos-
patase conjugated streptavidin (Pierce) diluted 1:1000
and revealed by the chromogenic substrate BCIP and NBT.
Immunohistochemistry
Immunoperoxidase staining was performed on histologi-
cal sections of mouse muscle prepared according to stand-
ard techniques. Miniantibodies from HEK 293T culture
supernatant were added to the sections, incubated for 30'
at room temperature in a moist chamber, followed by
biotinylated mAb SV5 diluted 1:1500 and peroxidase con-
jugated Streptavidin (Pierce) diluted 1:2500 and diami-
nobenzidine (DAB) as substrate.
DNA vaccination
Eight healthy, 8 week-old, female, BALB/cAnNHsd mice
were purchased from Harlan Italy. Mice were injected with
50 μl of bupivacaine 0.50% in isotonic NaCl into the
quadriceps muscle. Five days later, the bupivacaine
treated zones were injected with 50 μg of purified pMB-
MoG-2.8 and pMB-MoG-3.7 plasmidic DNA in 50 μl PBS.
A second injection with the same DNA quantity was made
after 14 days. Small volumes of blood were periodically
sampled from the mandibular artery and analyzed for the
presence of serum miniantibodies. Animal care and treat-
ment were conducted in conformity with institutional
guidelines in compliance with national and international
laws and policies (European Economic Community [EEC]
Council Directive 86/609; OJL 358; December 12, 1987).
In situ PCR
Frozen mouse quadriceps muscle tissue histological sec-
tions (5–10 μm) fixed on SuperFrost slides, were rehy-
drated to nuclease-free water through graded fresh
aqueous solution of ethanol (100%, 90%, 80%) then per-
meabilized in a 0.01% Triton-X 100/PBS solution for 2
min, and rinsed in PBS for 2 min. Primers VLPTL and
VHPT2 [3] and 5 mM dUTP Cy3fluorescent nucleotides
(Amersham Pharmacia) were used for direct labeling of
the amplicon. The direct fluorescent in situ PCR was per-
formed using the following cycle: 94°C, 30 s; 53°C, 60 s;
72°C, 60 s, repeated 15 times. After the PCR reaction the
slides were washed twice with PBS for 5 min and then
counter-stained with 4',6-Diamino-2-phenylindole
(DAPI) (Vectashield, Burlingame CA) and directly
observed under a fluorescent microscope (Olympus Opti-
cal, Shinjuku-ku, Tokyo, Japan).
Detection of anti-idiotype response
ELISA plates were coated with purified MB-MoG-2.8 and
MB-MoG-3.7, at 10 ug/ml for 15 h at 4°C. Wells were
blocked with 2% MBPS and incubated with sera of mice
diluted 1:50 with 2% MPBS, for 2 h at 37°C. After exten-
sive washing with PBST and PBS, secondary antibody anti-
mouse Fab-specific conjugated with HRP (Jackson Immu-
noresearch) diluted 1:5000 with MPBS was added and
incubated for 1 h at 37°C. All the immunocomplexes
were revealed with TMB (Sigma), the reaction was
stopped with 1 M sulphuric acid and read at OD450.
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